Neisseria gonorrhoeae: Difference between revisions
From IDWiki
Neisseria gonorrhoeae
(→: edited reference) |
(→: semantic citation) |
||
| Line 6: | Line 6: | ||
** About 50% resistance to [[fluoroquinolones]] |
** About 50% resistance to [[fluoroquinolones]] |
||
** Rates of MDR gonorrhea is increasing in Canada, mostly driven by [[azithromycin]] resistance |
** Rates of MDR gonorrhea is increasing in Canada, mostly driven by [[azithromycin]] resistance |
||
| − | ** XDR gonorrhea is still rare in Canada |
+ | ** XDR gonorrhea is still rare in Canada{{#scite:CCDR2019|type=journal|title=Multidrug-resistant and extensively drug-resistant gonorrhea in Canada, 2012–2016|journal=CCDR|year=2019|volume=45|issue=2/3|pages=45–53|doi=10.14745/ccdr.v45i23a01}} |
== Clinical Presentation == |
== Clinical Presentation == |
||
Revision as of 14:19, 27 August 2019
- Causes gonorrhea
Epidemiology
- Resistance
- About 50% resistance to fluoroquinolones
- Rates of MDR gonorrhea is increasing in Canada, mostly driven by azithromycin resistance
- XDR gonorrhea is still rare in Canada
Clinical Presentation
Anorectal gonorrhea
- Often asymptomatic
- Can cause anorectal pain, discharge, and pruritis
- Anal intercourse not required, especially in women
Disseminated gonococcal infection
- Classically presents with tenosynovitis (often of wrists) or frank arthritis, with pustular lesions
- Diagnosed with genital testing for gonorrhea, ± blood cultures or arthrocentesis
Diagnosis
- Resistance
- MDR gonorrhea: resistance to one of azithromycin or a cephalosporin
- XDR if resistance to both azithromycin and a cephalosporin
References
References
- ^ I Martin, P Sawatzky, V Allen, B Lefebvre, LMN Hoang, P Naidu, J Minion, P Van Caeseele, D Haldane, RR Gad, G Zahariadis, A Corriveau, G German, K Tomas, MR Mulvey. Multidrug-resistant and extensively drug-resistant Neisseria gonorrhoeae in Canada, 2012–2016. Canada Communicable Disease Report. 2019;45(2/3):45-53. doi:10.14745/ccdr.v45i23a01.
